According to the WeChat official account of Borui Biotech, youshi Biotech China and Zhejiang Borui Biopharmaceutical Co., Ltd. (referred to as "Borui Biotech") have signed a cooperation agreement for the commercial promotion of Beijiuzhuzhong antibody (product name: Beijiele) in the Chinese market. In July of this year, Beijiuzhuzhong antibody was approved by the National Medical Products Administration of china (NMPA) for the treatment of adult patients with active ankylosing spondylitis (AS) who do not respond well to or cannot tolerate conventional therapy, and in September it was subsequently approved for the treatment of adult patients with radiographically negative axial spondyloarthritis (nr-axSpA).